These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2569823)

  • 1. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
    Davey MJ
    Am J Med; 1989 Aug; 87(2A):36S-44S. PubMed ID: 2569823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of alpha blockade for blood pressure control.
    Davey M
    Am J Cardiol; 1987 May; 59(14):18G-28G. PubMed ID: 2884849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacological basis for the use of alpha 1-adrenoceptor antagonists in the treatment of essential hypertension.
    Davey MJ
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):5S-8S. PubMed ID: 2871856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacotherapeutics of doxazosin.
    Taylor SH
    Am J Med; 1989 Aug; 87(2A):2S-11S. PubMed ID: 2569822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL; Taylor AA; Nelson EB
    Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
    Hamilton CA; Reid JL; Vincent J
    Br J Pharmacol; 1985 Sep; 86(1):79-87. PubMed ID: 2864970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension.
    Wilner KD; Ziegler MG
    Am J Cardiol; 1987 May; 59(14):82G-86G. PubMed ID: 2884858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents.
    Graham RM
    Am J Cardiol; 1984 Jan; 53(3):16A-20A. PubMed ID: 6141721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
    Pool JL
    Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.
    Elliott HL; Meredith PA; Sumner DJ; McLean K; Reid JL
    Br J Clin Pharmacol; 1982 May; 13(5):699-703. PubMed ID: 6123342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plethysmographic effects of doxazosin in essential hypertensive patients.
    Mozzato MG; Buzzaccarini F; Casolino P; Valle R; Serena L; Rubino N; Casiglia E; Semplicini A; Pessina AC
    J Hypertens Suppl; 1989 Dec; 7(6):S290-1. PubMed ID: 2576669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications.
    Colucci WS
    Ann Intern Med; 1982 Jul; 97(1):67-77. PubMed ID: 6124197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
    Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
    Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
    Fulton B; Wagstaff AJ; Sorkin EM
    Drugs; 1995 Feb; 49(2):295-320. PubMed ID: 7537194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of doxazosin therapy on risk of coronary heart disease.
    Hansson L
    Am Heart J; 1988 Dec; 116(6 Pt 2):1832-7. PubMed ID: 2904759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.